Literature DB >> 26501157

Idiopathic infantile hypercalcemia: case report and review of the literature.

Brynn E Marks, Daniel A Doyle.   

Abstract

The widespread use of supplemental vitamin D has dramatically reduced the incidence of rickets. While generally considered a safe practice, there is potential for toxicity in patients with idiopathic infantile hypercalcemia (IIH). Inadequate 24-hydroxylase-enzyme activity renders these individuals unable to degrade active vitamin D, resulting in hypercalcemia due to increased intestinal calcium absorption, decreased renal calcium excretion, and increased osteoclastic bone activity. Clinicians should be aware that even therapeutic doses of vitamin D can prove harmful for patients with CYP24A1 mutations. Studies have also demonstrated a link between inadequate 24-hydroxylase activity and nephrocalcinosis, renal insufficiency, and calcium containing kidney stones, further emphasizing the importance of early recognition of this disease and judicious use of vitamin D. We present a case with an interesting diagnostic algorithm used to diagnose IIH when given an incomplete history and subsequently review the existing literature on the subject.

Entities:  

Mesh:

Year:  2016        PMID: 26501157     DOI: 10.1515/jpem-2015-0133

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  3 in total

Review 1.  Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.

Authors:  Peter J Tebben; Ravinder J Singh; Rajiv Kumar
Journal:  Endocr Rev       Date:  2016-09-02       Impact factor: 19.871

2.  The cause of severe hypercalcaemia resistant to pamidronate treatment: subcutaneous fat necrosis with no visible skin lesion.

Authors:  Saime Ergen Dibeklioğlu; Veysel Nijat Baş; Emine Esin Yalınbaş; Sermin Tok Umay
Journal:  Sudan J Paediatr       Date:  2022

3.  Optimal bone fracture repair requires 24R,25-dihydroxyvitamin D3 and its effector molecule FAM57B2.

Authors:  Corine Martineau; Roy Pascal Naja; Abdallah Husseini; Bachar Hamade; Martin Kaufmann; Omar Akhouayri; Alice Arabian; Glenville Jones; René St-Arnaud
Journal:  J Clin Invest       Date:  2018-07-16       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.